Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant IL-6R (Tocilizumab Biosimilar) anticorps

L’anticorps Lapin Chimeric anti-IL-6R (Tocilizumab Biosimilar) a été validé pour ELISA et InhA. Il convient pour détecter IL-6R (Tocilizumab Biosimilar) dans des échantillons de Humain.
N° du produit ABIN5668254

Aperçu rapide pour Recombinant IL-6R (Tocilizumab Biosimilar) anticorps (ABIN5668254)

Antigène

IL-6R (Tocilizumab Biosimilar)

Type d'anticorp

Recombinant Antibody

Reactivité

Humain

Hôte

  • 3
  • 1
  • 1
Lapin

Clonalité

  • 4
  • 1
Chimeric

Conjugué

  • 4
  • 1
Cet anticorp IL-6R (Tocilizumab Biosimilar) est non-conjugé

Application

  • 4
  • 2
  • 1
ELISA, Inhibition Assay (InhA)

Clone

RhPM-1
  • Fonction

    Anti-IL-6 receptor [rhPM-1 (Tocilizumab)], Rabbit IgG, kappa

    Specificité

    Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.

    Attributs du produit

    Original Species of Ab: Human

    Original Format of Ab: IgG1

    Purification

    Protein A affinity purified

    Pureté

    > 98 % as determined by SDS-PAGE

    niveau d'endotoxine

    Endotoxin is < 1.0 EU/mg as determined by the LAL method

    Immunogène

    The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.

    Isotype

    IgG kappa
  • Indications d'application

    This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958, 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925). The original antibody was used for an in vivo study on ALS. Here they showed that this antibody does not affect all patients the same way. Here it was shown that the antibody lowers inflammation in patients with high inflammation and increases inflammation in patients with low inflammation (Fiala et al., 2013, PMID:23844337). tocilizumab inhibited both the transcription and secretion of cytokines and chemokines induced by apo-G37R. This showed powerful effects on the inflammation in ALS PMBC (Mizwicki et al., 2012, PMID: 23383400)

    Commentaires

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    PBS with 0.02 % Proclin 300.

    Agent conservateur

    ProClin

    Précaution d'utilisation

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Antigène

    IL-6R (Tocilizumab Biosimilar)

    Classe de substances

    Biosimilar

    Sujet

    IL6R, IL-6R, CD126, MRA, atlizumab, TCZ, Interleukin-6 receptor subunit alpha, IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, PM1, PM-1

    UniProt

    P08887
Vous êtes ici:
Chat with us!